DRIO - ラボスタイル・イノベ―ションズ （DarioHealth Corp.）

New accounts demonstrate continued demand for integrated and holistic digital chronic condition management solutions NEW YORK , Sept. 20, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO ) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today two new employer contracts, including one for the full suite of integrated solutions. The new accounts are scheduled to launch in late 2022 and early 2023. Through the first contract, Dario will deliver its full suite of integrated solutions to a leading global manufacturer. The second contract is for Dario''s behavioral health solution with an integrated Employee Assistance Program (EAP). This contract originated through an existing employer channel partnership and demonstrates the value of Dario''s recently announced strategic relationships in the market. The new multi-chronic account also reflects the growing demand for Dario''s integrated, holistic digital health solutions to address commonly co-occurring chronic conditions.

Benzinga Pro data, DarioHealth (NASDAQ: DRIO ) reported Q2 sales of $6.18 million. Earnings fell to a loss of $18.03 million, resulting in a 13.27% decrease from last quarter. DarioHealth collected $8.06 million in revenue during Q1, but reported earnings showed a $15.92 million loss. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com

In Friday’s session, DarioHealth Corp. (NASDAQ:DRIO) marked $4.45 per share, down from $4.58 in the previous session. While DarioHealth Corp. has underperformed by -2.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DRIO fell by -68.12%, with highs and lows ranging from $19.39 to $4.11, whereas […]

DarioHealth Corp. (NASDAQ:DRIO)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 1.23. At the close of trading, the stock’s price was $4.90, to imply a decrease of -4.11% or -$0.21 in intraday trading. The DRIO share’s 52-week high remains $19.39, putting it -295.71% down since that peak … DarioHealth Corp. (NASDAQ: DRIO) Stock Has Dropped -24.73% Over The Month – Is There Room For Growth? Read More »

https://www.investing.com/news/pro/dariohealth-corp-pt-lowered-to-11-at-stifel-432SI-2873693

DarioHealth (DRI) a digital therapeutics company focused on chronic condition added over 11% on Friday in reaction to results from three new studies highlighting the benefits of…

The studies demonstrated significant improvement in glucose control and reductions in blood pressure for users managing diabetes and hypertension and improvement in clinical measures for users with diabetes, stress and depression. The third study demonstrates that the Dario solution has…

DarioHealth (DRIO) said on Thursday it had bagged two new contracts to provide digital therapeutics solutions to a national employer and a provider, both of which are expected to…

Upgrades B of A Securities upgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE: RBA ) from Underperform to Neutral. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.46, compared to $0.25 from the year-ago quarter. The current stock performance of Ritchie Bros Auctioneers shows a 52-week-high of $76.17 and a 52-week-low of $48.65. Moreover, at the end of the last trading period, the closing price was at $58.91. For Ford Motor Co (NYSE: F ), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. For the first quarter, Ford Motor had an EPS of $0.38, compared to year-ago quarter EPS of $0.89. The current stock performance of Ford Motor shows a 52-week-high of $25.87 and a 52-week-low of $11.28. Moreover, at the end of the last trading period, the closing price was at $12.44. For PaySign Inc (NASDAQ: PAYS ), Barrington Research upgraded the previous rating of Market Perform to Outperform. For the first quarter, PaySign had an EPS of $0.01, compared to year-ago quarter EPS of $0.03.

DarioHealth Corp. (NASDAQ:NASDAQ:DRIO) Q1 2022 Earnings Conference Call May 12, 2022 08:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive…

DarioHealth press release (DRIO): Q4 pro-forma gross profit was $1.33M, or 22.1% of revenues, for the three months ended December 31, 2021.Revenue of $6.03M (+189.9% Y/Y).Non-GAAP…

DarioHealth (NASDAQ: DRIO ) reported its Q4 earnings results on Tuesday, March 22, 2022 at 06:30 AM. Here''s what investors need to know about the announcement. Earnings DarioHealth missed estimated earnings by 2.83%, reporting an EPS of $-1.09 versus an … Full story available on Benzinga.com

DarioHealth press release (DRIO): FY GAAP EPS of -$4.07 beats by $0.65.Revenue of $20.51M (+170.9% Y/Y) misses by $0.11M.Shares -0.77% PM.

Image sourced from Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. DarioHealth Corp. (NASDAQ: DRIO ) announced that it has entered into a strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario''s full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution, significantly increasing Dario''s sales reach in the health plan market and selectively in the employer channel. In addition, the agreement calls for Dario and Sanofi to develop new … Full story available on Benzinga.com